Liège, Belgium 30 June 2016 – Mithra announces today that the first patient has been screened for enrolment in the European Phase III clinical trials for its Estetrol-based product candidate Estelle® (E4/DRSP). The screening of this first patient marks the launch of the Estelle® (E4/DRSP) Phase III clinical trial in Europe.
Brussels, Belgium 29 June 2016 – Mithra Pharmaceuticals hosts its 2016 Investor Day today in Brussels. Through interviews with the CEO François Fornieri, members of the Executive Management and of the Scientific Committee, Mithra provides an update on its strategy and business model, as well as on its Research and Development projects one year after its Initial Public Offering.
Liège, Belgium 28 June 2016 – Mithra announces that it signed a non-exclusive License and Supply Agreement with the Hungarian company Gedeon Richter for its product Tibelia®. Under the terms of this contract, Mithra grants Gedeon a non-exclusive license for the commercialization of Tibelia® in Italy, Switzerland, Spain, Germany, Belgium and Luxembourg.
- LoI between Mithra and Fuji, market leader in Japan, for Estetrol-based products in Women’s Health; multiple indications to be determined in common agreement
- Japanese clinical trials to be conducted and financed by Fuji
- Potential milestones in the double-digit million EUR range
Liège, Belgium 24 June 2016 – Mithra Pharmaceuticals is pleased to announce it has signed a Letter of Intent with Fuji Pharmaceuticals to work towards a broad partnership on Estetrol in women’s health, in multiple indications to be determined in common agreement. Both parties intend to finalize their partnership in an agreement before the end of this year. This important partnership (involving investments and potential milestones in the double-digit million range) between Mithra and Fuji Pharmaceuticals, the market leader in Women’s Health in Japan, validates Mithra’s strategy of seeking out the Women’s Health leaders in markets around the world.
Rue Saint-Georges 5
Tel. : +32 (0)4 349 28 22
Fax : +32 (0)4 349 28 21
Email : firstname.lastname@example.org